Shots:

• PerkinElmer to acquire BioLegend for ~$5.25B in cash and stock transaction. The acquisition is expected to close by the end of 2021
• The acquisition will allow PerkinElmer to build its growth in areas such as clinical diagnostics and food safety testing
• With the acquisition- BioLegend’s San Diego- California-based campus will become the global center for the development of chemical reagents used in medical research for the combined company

­ Ref: PRNewswire | Image: BioLegend